X4 PHARMACEUTICALS INC XFOR 深 滬
等待開盤 11-03 09:30:00 美东时间
4.04
+0.050
+1.25%
華盛通- 最 高4.11
- 今 開3.99
- 成交量 64.94万股
- 最 低 3.91
- 昨 收 3.99
- 總市值 4608.99万
- 52周最高 26.829
- 市盈率 靜 --
- 換手率 0.01%
- 52周最低 1.35
- 委 比 -16.21%
- 總股本 1140.84万
- 歷史最高 717.90
- 量 比 0.12
- 振 幅 5.01%
- 歷史最低 3.91
- 每 手 1
- 風險率 6.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million
X4 Pharmaceuticals completed a public offering of 52,844,000 shares at $2.90 per share, raising approximately $155.3 million before expenses. The offering included an additional 6,984,000 shares and pre-funded warrants for 700,000 shares. Leerink Partners, Stifel, and Guggenheim Securities acted as joint bookrunners. The company plans to use the proceeds for its operations, including advancing its pipeline in rare hematology diseases.
10-27 23:05
X4 Pharmaceuticals drops 5%, prices $135M equity
X4 Pharmaceuticals (NASDAQ:XFOR) priced its previously announced underwritten public offering of 45.86M shares at $2.90 and warrants to purchase up to 700K shares at a public offering price of $2.899 ...
10-24 14:52
X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering
X4 Pharmaceuticals has priced its underwritten public offering of 45.86 million shares at $2.90 per share, with pre-funded warrants for up to 700,000 shares at $2.899. The offering is expected to raise approximately $135 million before expenses and close on October 27. Proceeds will fund pivotal Phase 3 development of mavorixafor for chronic neutropenic disorders and general corporate purposes.
10-24 04:37
X4 Pharmaceuticals to reduce 50% of workforce
X4 Pharmaceuticals (NASDAQ:XFOR) has announced a restructuring program to align resources with its long-term strategy to complete the Phase 3 4WARD trial for chronic neutropenia. The plan includes cut...
09-17 19:33
X4 Pharmaceuticals Announces Major Strategic Restructuring
X4 Pharmaceuticals ( ($XFOR) ) has provided an update. On September 17, 2025, X...
09-17 19:29
X4 Pharmaceuticals Announces Strategic Restructuring With 50% Workforce Reduction Expected To Deliver $13M Annualized Cost Savings
Organizational restructuring including a 50% reduction in workforce that is anticipated to result in annualized cost savings of approximately $13MJohn Volpone appointed Chief Operating Officer, in addition to his current
09-17 19:12
X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation
X4 Pharmaceuticals announced a 50% workforce reduction, expected to save $13M annually, as part of strategic restructuring to focus on completing the 4WARD Phase 3 trial for chronic neutropenia. John Volpone was appointed Chief Operating Officer alongside his role as President, while Dr. Adam Craig will oversee clinical development. Natasha Thoren, Mary DiBiase, and Mark Baldry are leaving, and Dr. Christophe Arbet-Engels is resigning for persona...
09-17 11:00
Stifel Maintains Buy on X4 Pharmaceuticals, Lowers Price Target to $9
Stifel analyst Stephen Willey maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and lowers the price target from $30 to $9.
08-29 21:13
X4 Pharmaceuticals Announces Board Resignations and Appointments
The latest announcement is out from X4 Pharmaceuticals ( ($XFOR) ). On August 2...
08-25 20:27
X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement
X4 Pharmaceuticals completed a $85 million private placement of shares and warrants, up from the initial $60 million target, to include an investor with a pre-existing investment right. The financing was led by Coastlands Capital, supported by existing and new life sciences investors. Proceeds will fund the continued development of mavorixafor for chronic neutropenia and WHIM syndrome commercialization.
08-13 11:00
